News

Sublingual immunotherapy is coming soon


 

EXPERT ANALYSIS FROM THE PULMONARY AND ALLERGY UPDATE

Dr. Nelson’s prediction that these three SLIT products are headed for FDA approval this spring stems from enthusiastic endorsements by the agency’s Allergenic Products Advisory Committee. The SLIT grass allergy products were recommended unanimously, and the ragweed SLIT also received a strongly favorable vote.

He reported serving as a consultant to Merck, Pearl Therapeutic, and Circassia.

bjancin@frontlinemedcom.com

Pages

Next Article:

Omalizumab reduces epinephrine need during oral immunotherapy